| Literature DB >> 11257582 |
M D. Hughes1, M Hussain, Q Nawaz, P Sayyed, S Akhtar.
Abstract
The design and development of antisense oligonucleotides and ribozymes for the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. Improvements in oligonucleotide chemistry have led to the synthesis of nucleic acids that are relatively stable in the biological milieu. However, advances in cellular targeting and intracellular delivery will probably lead to more widespread clinical applications. This review looks at recent advances in the in vitro and in vivo delivery of antisense oligodeoxynucleotides and ribozymes.Entities:
Year: 2001 PMID: 11257582 DOI: 10.1016/s1359-6446(00)00326-3
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851